Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.
Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses apooled analysisof eribulin for the treatment of patients with breast cancer.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More